uniQure has announced the outcomes of its recent clinical trial for a gene therapy aimed at treating epilepsy, revealing a combination of positive and negative results. The trial assessed the safety and efficacy of the therapy in patients with epilepsy, with some participants showing improvement in seizure control while others did not experience significant benefits. The company is currently analyzing the data to better understand the varying responses among participants. Further details regarding the implications of these findings for future research and development are expected to be released in subsequent communications.
Don't miss out on breaking stories and in-depth articles.
